WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third-quarter revenue despite concerns over a US bill seeking to ...

Chinese electric-car maker Li Auto and pharmaceutical company WuXi Apptec will join the Hang Seng Index as new constituents next month, according to the latest quarterly review by Hong Kong’s ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs from federal funding and ...

WuXi AppTec’s shares closed up almost 12 per cent to HK$67.10 on Friday, while shares of subsidiary WuXi Biologics rose nearly 15 per cent to HK$21.45. Those gains were made after Financial ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science ...

Shanghai-based WuXi AppTec focuses on drug discovery, development, and manufacturing. Founded in 2001 as WuXi PharmaTech, the company rebranded to its current name after acquiring the U.S.-based ...